BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND NPM1, NPM, 4869, ENSG00000181163, P06748, B23, MGC104254 AND Prognosis
74 results:

  • 1. CCDC86 promotes the aggressive behavior of nasopharyngeal carcinoma by positively regulating EGFR and activating the PI3K/Akt signaling.
    Wang Z; Zhou T; Chen X; Zhu X; Liao B; Liu J; Li S; Tan T; Liu Y
    Neoplasma; 2023 Dec; 70(6):761-776. PubMed ID: 38247332
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Phosphoproteome analysis of cerebrospinal fluid extracellular vesicles in primary central nervous system lymphoma.
    Deng Y; Li Q; Sun J; Ma L; Ding Y; Cai Y; Iliuk A; Chen B; Xie Z; Tao WA
    Analyst; 2023 Jul; 148(15):3594-3602. PubMed ID: 37403840
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Wilms' tumor 1 expression combined with genetic mutations for prognostic assessment in MDS.
    Pan D; Zhao W; Jiang Q; Yin C; He H; Liao L; Ye J; Dai M
    Leuk Lymphoma; 2023 Apr; 64(4):856-864. PubMed ID: 36905177
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing.
    Xu J; Hao Z; Chen X; Hong M; Muyey DM; Chen X; Wang H
    Leuk Lymphoma; 2022 Oct; 63(10):2321-2329. PubMed ID: 35652795
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Primary Central Nervous System Anaplastic Large Cell lymphoma, ALK Positive.
    Ahrendsen JT; Ta R; Li J; Weinberg OK; Ferry JA; Hasserjian RP; Meredith DM; Varma H; Sadigh S; Michaels PD
    Am J Clin Pathol; 2022 Aug; 158(2):300-310. PubMed ID: 35460414
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Upregulation of
    Eshibona N; Giwa A; Rossouw SC; Gamieldien J; Christoffels A; Bendou H
    Leuk Lymphoma; 2022 Aug; 63(8):1897-1906. PubMed ID: 35249471
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Cytogenetic abnormalities in
    Fu W; Huang A; Xu L; Peng Y; Gao L; Chen L; Chen J; Tang G; Yang J; Ni X
    Leuk Lymphoma; 2022 Aug; 63(8):1956-1963. PubMed ID: 35227153
    [No Abstract]    [Full Text] [Related]  

  • 8. FLT3-ITD Allele Frequency Is an Independent Prognostic Factor for Poor Outcome in FLT3-ITD-Positive AML Patients.
    Shafik NF; Darwish AD; Allam RM; Elsayed GM
    Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):676-685. PubMed ID: 34108128
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Clinicopathological Evaluation of Acute Leukemias in a Tertiary Care Hospital: A Cross-Sectional Study.
    Patel GN; Gudur R; Gudur A; Oswal RM; Kanethkar S
    Turk Patoloji Derg; 2021; 37(2):145-153. PubMed ID: 33973643
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Comprehensive Genomic Analysis of Noonan Syndrome and Acute Myeloid Leukemia in Adults: A Review and Future Directions.
    Alhumaid MS; Dasouki MJ; Ahmed SO; AbalKhail H; Hagos S; Wakil S; Hashmi SK
    Acta Haematol; 2020; 143(6):583-593. PubMed ID: 32541138
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Clinical, Histologic, and Molecular Characteristics of Anaplastic lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell lymphoma.
    Melchers RC; Willemze R; van de Loo M; van Doorn R; Jansen PM; Cleven AHG; Solleveld N; Bekkenk MW; van Kester MS; Diercks GFH; Vermeer MH; Quint KD
    Am J Surg Pathol; 2020 Jun; 44(6):776-781. PubMed ID: 32412717
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients.
    Guolo F; Minetto P; Clavio M; Marcolin R; Miglino M; Passannante M; Caviglia F; Ballerini F; Tedone E; Kunkl A; Mangerini R; Contini P; Colombo N; Cagnetta A; Cea M; Carminati E; Pugliese G; Gobbi M; Lemoli RM
    Leuk Lymphoma; 2020 Jul; 61(7):1695-1701. PubMed ID: 32186422
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. AML in Saudi Arabia: Analysis According to the European LeukaemiaNet 2017 Cytogenetic Classification.
    Alabdulwahab AS; Elsayed HG; Sherisher MA; Zeeneldin A; Elbjeirami WM
    Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):e212-e220. PubMed ID: 32127298
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Genomic subtyping and therapeutic targeting of acute erythroleukemia.
    Iacobucci I; Wen J; Meggendorfer M; Choi JK; Shi L; Pounds SB; Carmichael CL; Masih KE; Morris SM; Lindsley RC; Janke LJ; Alexander TB; Song G; Qu C; Li Y; Payne-Turner D; Tomizawa D; Kiyokawa N; Valentine M; Valentine V; Basso G; Locatelli F; Enemark EJ; Kham SKY; Yeoh AEJ; Ma X; Zhou X; Sioson E; Rusch M; Ries RE; Stieglitz E; Hunger SP; Wei AH; To LB; Lewis ID; D'Andrea RJ; Kile BT; Brown AL; Scott HS; Hahn CN; Marlton P; Pei D; Cheng C; Loh ML; Ebert BL; Meshinchi S; Haferlach T; Mullighan CG
    Nat Genet; 2019 Apr; 51(4):694-704. PubMed ID: 30926971
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and npm1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.
    Assaf N; El-Cheikh J; Bazarbachi A; Salem Z; Farra C; Chakhachiro Z; Nassif S; Zaatari G; Mahfouz R
    Mol Biol Rep; 2019 Apr; 46(2):2003-2011. PubMed ID: 30701458
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. npm1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome.
    Handschuh L; Wojciechowski P; Kazmierczak M; Marcinkowska-Swojak M; Luczak M; Lewandowski K; Komarnicki M; Blazewicz J; Figlerowicz M; Kozlowski P
    J Transl Med; 2018 Aug; 16(1):232. PubMed ID: 30126426
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. FLT3-TKD Mutations Associated With npm1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.
    Perry M; Bertoli S; Rocher C; Hayette S; Ducastelle S; Barraco F; Labussière-Wallet H; Salles G; Recher C; Thomas X; Paubelle E
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e545-e550. PubMed ID: 30082225
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study.
    Hidaka D; Onozawa M; Hashiguchi J; Miyashita N; Kasahara K; Fujisawa S; Hayase E; Okada K; Shiratori S; Goto H; Sugita J; Nakagawa M; Hashimoto D; Kahata K; Endo T; Yamamoto S; Tsutsumi Y; Haseyama Y; Nagashima T; Mori A; Ota S; Sakai H; Ishihara T; Imai K; Miyagishima T; Kakinoki Y; Kurosawa M; Kobayashi H; Iwasaki H; Shimizu C; Kondo T; Teshima T
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e469-e479. PubMed ID: 30082223
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
    Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.